- Home
- IONS vs CHKP Comparison
IONS vs CHKP Comparison
Compare IONS & CHKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IONS | CHKP |
|---|---|---|
| Founded | 1989 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 14.1B |
| IPO Year | 1996 | 1997 |
Fundamental Metrics
Financial Performance| Metric | IONS | CHKP |
|---|---|---|
| Price | $44.46 | $132.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 20 |
| Target Price | $93.36 | ★ $199.50 |
| AVG Volume (30 Days) | ★ 3.2M | 961.5K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.31 |
| Revenue Next Year | $77.99 | $6.03 |
| P/E Ratio | ★ N/A | $17.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.66 | $112.23 |
| 52 Week High | $86.74 | $210.66 |
Technical Indicators
Market Signals| Indicator | IONS | CHKP |
|---|---|---|
| Relative Strength Index (RSI) | 26.02 | 50.17 |
| Support Level | N/A | $129.19 |
| Resistance Level | $78.11 | $135.50 |
| Average True Range (ATR) | 2.40 | 4.65 |
| MACD | -1.47 | 0.01 |
| Stochastic Oscillator | 3.39 | 40.89 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About CHKP Check Point Software Technologies Ltd.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.